MDxHealth SA ADR Cash Flow Conversion Efficiency
MDxHealth SA ADR cash flow conversion efficiency. Based on the latest financial reports, MDxHealth SA ADR (MDXH) has a cash flow conversion efficiency ratio of 0.192x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.85 Million) by net assets ($-30.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MDxHealth SA ADR (2004–2025)
Cash flow conversion efficiency of MDxHealth SA ADR from 2004 to 2025. This chart illustrates how MDxHealth SA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of MDxHealth SA ADR for real-time trading data and today's change.
MDxHealth SA ADR Cash Flow Conversion Ratio Explained
MDxHealth SA ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MDxHealth SA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MDxHealth SA ADR ranked by their cash flow conversion efficiency. Also see MDxHealth SA ADR market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.070x |
|
Endomines Finland Oyj
HE:PAMPALO
|
0.142x |
|
WCT Holdings Bhd
KLSE:9679
|
-0.027x |
|
Stellar Resources Ltd
AU:SRZ
|
-0.353x |
|
Tirathai Public Company Limited
BK:TRT
|
0.287x |
|
Wheels Up Experience Inc
NYSE:UP
|
0.214x |
|
ARRAIL GROUP LTD.
F:I1D
|
N/A |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
0.069x |
Annual Cash Flow Conversion Efficiency for MDxHealth SA ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of MDxHealth SA ADR from 2004 to 2025. Review MDXH cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.09 Million | $-10.42 Million | 0.861x | +168.99% |
| 2024-12-31 | $14.84 Million | $-18.53 Million | -1.249x | +58.14% |
| 2023-12-31 | $7.21 Million | $-21.50 Million | -2.982x | +18.57% |
| 2022-12-31 | $9.31 Million | $-34.12 Million | -3.663x | -661.83% |
| 2021-12-31 | $46.90 Million | $-22.55 Million | -0.481x | +86.11% |
| 2020-12-31 | $5.85 Million | $-20.24 Million | -3.461x | -206.28% |
| 2019-12-31 | $19.72 Million | $-22.29 Million | -1.130x | -106.34% |
| 2018-12-31 | $52.12 Million | $-28.54 Million | -0.548x | -127.37% |
| 2017-12-31 | $43.55 Million | $-10.49 Million | -0.241x | +23.40% |
| 2016-12-31 | $52.74 Million | $-16.59 Million | -0.314x | +3.30% |
| 2015-12-31 | $44.26 Million | $-14.39 Million | -0.325x | +58.24% |
| 2014-12-31 | $23.78 Million | $-18.51 Million | -0.779x | -35.45% |
| 2013-12-31 | $24.54 Million | $-14.11 Million | -0.575x | +18.11% |
| 2012-12-31 | $16.02 Million | $-11.25 Million | -0.702x | -21.14% |
| 2011-12-31 | $14.67 Million | $-8.50 Million | -0.580x | +23.56% |
| 2010-12-31 | $14.26 Million | $-10.81 Million | -0.758x | -11.36% |
| 2009-12-31 | $26.94 Million | $-18.34 Million | -0.681x | -138.61% |
| 2008-12-31 | $45.44 Million | $-12.96 Million | -0.285x | +13.86% |
| 2007-12-31 | $49.75 Million | $-16.48 Million | -0.331x | -104.43% |
| 2006-12-31 | $42.21 Million | $-6.84 Million | -0.162x | +60.09% |
| 2005-12-31 | $11.95 Million | $-4.85 Million | -0.406x | +53.41% |
| 2004-12-31 | $7.04 Million | $-6.14 Million | -0.871x | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more